Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Vertex Pharmaceuticals Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1989-01-01

Employees: 5.4K

Market Cap: $123.9B

Website: http://www.vrtx.com

Clinical Trials

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: Telaprevir
Drug: Ribavirin
Drug: Matching Placebo
Drug: Pegylated Interferon Alfa 2a

First Posted Date: 2007-01-11

Last Posted Date: 2014-08-05

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 465

Registration Number: NCT00420784

Locations: 🇺🇸
Birmingham Gastroenterology Associates, Birmingham, Alabama, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
USC, Los Angeles, California, United States

and more 31 locations

A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Phase 2

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2006-11-03

Last Posted Date: 2007-12-07

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 120

Registration Number: NCT00395577

Locations: 🇸🇮
Call For Information, Ljubljana, Slovenia
🇵🇱
Call for Information, Torun, Poland

A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.

Phase 1

Completed

Conditions: Hepatitis C, Chronic

First Posted Date: 2006-10-18

Last Posted Date: 2009-09-24

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 36

Registration Number: NCT00389298

Locations: 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada
🇨🇦
Liver and Intestinal Research Centre, Vancouver, British Columbia, Canada
🇨🇦
Ottawa Hospital; General Campus, Ottawa, Ontario, Canada

and more 1 locations

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Ribavirin
Drug: Pegylated Interferon Alfa 2a
Drug: Placebo
Drug: Telaprevir

First Posted Date: 2006-09-06

Last Posted Date: 2014-07-23

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 334

Registration Number: NCT00372385

Locations: 🇩🇪
Call For Information, Call For Information, Germany
🇬🇧
Call for Information, Call for Information, United Kingdom

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Telaprevir
Drug: Ribavirin
Drug: Pegylated Interferon Alfa 2a
Other: Placebo

First Posted Date: 2006-06-13

Last Posted Date: 2014-07-23

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 263

Registration Number: NCT00336479

Locations: 🇺🇸
Call For Information, Durham, North Carolina, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Stanford University Liver Research, Palo Alto, California, United States

and more 25 locations

Trial of AVN-944 in Patients With Advanced Hematologic Malignancies

Phase 1

Completed

Conditions: Acute Leukemia
Chronic Leukemia
Multiple Myeloma
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Waldenstrom's Macroglobulinemia

First Posted Date: 2006-01-10

Last Posted Date: 2011-08-04

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 72

Registration Number: NCT00273936

Locations: 🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸
George Washington University, Washington, District of Columbia, United States

and more 2 locations

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Phase 2

Completed

Conditions: Hepatitis C

First Posted Date: 2005-12-06

Last Posted Date: 2007-12-21

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 12

Registration Number: NCT00262483

Locations: 🇵🇷
Call for information, Santurce, Puerto Rico

VX-950 and Peginterferon for Hepatitis C

Phase 1

Completed

Conditions: Hepatitis C

First Posted Date: 2005-11-09

Last Posted Date: 2007-12-21

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 20

Registration Number: NCT00251199

Locations: 🇳🇱
Call for information, Amsterdam, Netherlands

Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Phase 2

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2005-09-20

Last Posted Date: 2007-12-07

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 300

Registration Number: NCT00205478

Locations: 🇧🇬
Medical University - Sofia, Sofia, Bulgaria
🇧🇬
Military Medical Academy - Sofia, Sofia, Bulgaria
🇧🇬
Transport Hospital, Sofia, Bulgaria

and more 39 locations

Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765

Phase 2

Completed

Conditions: Psoriasis

First Posted Date: 2005-09-20

Last Posted Date: 2007-12-05

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 64

Registration Number: NCT00205465

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy